As chronic liver disease becomes more widespread, researchers at Science Tokyo have developed a lab-grown organoid that ...

To execute this disruptive initiative, Greenstone Biosciences, Inc., a Palo Alto-based biotechnology leader founded by Dr. Joseph C. Wu of Stanford University and recently partnered with NVIDIA 1,2, ...

BrainXell Therapeutics today announced the disclosure of its first scientific data, which will be presented at two conferences this month: the Cell Symposia | Gene and Cell-Based Therapies: Progress ...

As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were ...

The cell therapy field has long held a transformative ambition: to create "off-the-shelf" treatments that can reach not just ...

Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026PHOENIX, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Creative Medical ...

As chronic liver disease becomes more widespread, researchers at Science Tokyo have developed a lab-grown organoid that ...

Most people are born with two functioning copies of each gene-one inherited from each parent. In many cases, having just one ...

Detailed price information for Fate Therapeutics (FATE-Q) from The Globe and Mail including charting and trades.

Answer ALS today announced the full release of its comprehensive ALS clinical and multi-omics dataset, marking the culmination of a multi-year research program and a groundbreaking collaboration with ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on ...